Doxycycline Tablets

Type of Posting	Revision Bulletin
Posting Date	30–Mar–2018
Official Date	01–Apr–2018
Expert Committee	Chemical Medicines Monographs 1
Reason for Revision	Compliance

In accordance with the Rules and Procedures of the 2015–2020 Council of Experts, the Chemical Medicines Monographs 1 Expert Committee has revised the Doxycycline Tablets monograph. The purpose of the revision is to add *Dissolution Test 2* for a generic product approved by the FDA. A *Labeling* section was also added.

The Doxycycline Tablets Revision Bulletin supersedes the currently official monograph. The Revision Bulletin will be incorporated in *USP 42–NF 37*.

Should you have any questions, please contact Praveen Pabba, Ph.D. Scientific Liaison (301-816-8540 or pkp@usp.org).

Doxycycline Tablets

DEFINITION

Doxycycline Tablets contain NLT 90.0% and NMT 120.0% of the labeled amount of doxycycline ($C_{22}H_{24}N_2O_8$).

IDENTIFICATION

- **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.
- **B.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.

ASSAY

- **PROCEDURE**

Protect solutions containing doxycycline from light.

Solution A: Transfer 3.1 g of monobasic potassium phosphate, 0.5 g of edetate disodium, and 0.5 mL of triethylamine to a 1000-mL volumetric flask. Add about 850 mL of water and mix. Dilute with water to volume and adjust with 1 N sodium hydroxide to a pH of 8.5 ± 0.1.

Solution B: Methanol

Mobile phase: See *Table 1*.

Table 1

Time (min)	Solution A (%)	Solution B (%)
0.0	90	10
2.0	90	10
4.0	60	40
6.0	90	10
9.0	90	10

Diluent: 0.01 N hydrochloric acid

Standard solution: 0.12 mg/mL of USP Doxycycline Hyclate RS in *Diluent*. Sonicate as needed to dissolve.

Sample solution: Nominally 0.1 mg/mL of doxycycline from NLT 20 Tablets prepared as follows. Transfer a suitable portion of finely powdered Tablets to a suitable volumetric flask. Add 50% of the final volume of *Diluent*, dissolve, dilute with *Diluent* to volume, and mix well. Centrifuge a portion of the solution and use the supernatant. [NOTE—The use of a centrifuge speed at 3,000 rpm for 10 min may be suitable.]

Chromatographic system
(See *Chromatography* ⟨621⟩*, System Suitability*.)
Mode: LC
Detector: UV 270 nm. For *Identification B*, a diode array detector may be used in the wavelength range of 200–400 nm.
Column: 2.1-mm × 5-cm; 1.7-µm packing L7. [NOTE—A 1.7-µm guard column with packing L7 was used during method validation.]
Column temperature: 60°
Flow rate: 0.6 mL/min
Injection volume: 5 µL

System suitability
Sample: *Standard solution*
Suitability requirements
Tailing factor: NMT 1.5
Relative standard deviation: NMT 2.0%

Analysis
Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of doxycycline ($C_{22}H_{24}N_2O_8$) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times P \times F \times 100$$

r_U = peak response from the *Sample solution*
r_S = peak response from the *Standard solution*
C_S = concentration of USP Doxycycline Hyclate RS in the *Standard solution* (mg/mL)
C_U = nominal concentration of doxycycline in the *Sample solution* (mg/mL)
P = potency of doxycycline in USP Doxycycline Hyclate RS (µg/mg)
F = conversion factor, 0.001 mg/µg

Acceptance criteria: 90.0%–120.0%

PERFORMANCE TESTS

Change to read:

- **DISSOLUTION** ⟨711⟩

▲Test 1▲ (RB 1-Apr-2018)
Medium: 0.01 N hydrochloric acid; 900 mL
Apparatus 2: 75 rpm
Time: 60 min
Standard solution: 0.01 mg/mL of doxycycline from USP Doxycycline Hyclate RS in *Medium*
Sample solution: Pass a portion of the solution under test through a suitable filter. Dilute a portion of the filtrate with *Medium* to a concentration that is similar to that of the *Standard solution*.

Instrumental conditions
(See *Ultraviolet-Visible Spectroscopy* ⟨857⟩.)
Mode: UV
Analytical wavelength: 268 nm
Cell: 1 cm
Blank: *Medium*

Analysis
Samples: *Standard solution* and *Sample solution*
Determine the percentage of the labeled amount of doxycycline ($C_{22}H_{24}N_2O_8$) dissolved:

$$\text{Result} = (A_U/A_S) \times (C_S/L) \times V \times P \times 100$$

A_U = absorbance of the *Sample solution*
A_S = absorbance of the *Standard solution*
C_S = concentration of USP Doxycycline Hyclate RS in the *Standard solution* (mg/mL)
L = label claim (mg/Tablet)
V = volume of *Medium*, 900 mL
P = potency of doxycycline in USP Doxycycline Hyclate RS (µg/mg)

Tolerances: NLT 85% *(Q)* of the labeled amount of doxycycline ($C_{22}H_{24}N_2O_8$) is dissolved.

▲Test 2: If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 2*.
Protect solutions containing doxycycline from light.
Medium: 0.01 N hydrochloric acid; 900 mL
Apparatus 2: 75 rpm
Time: 15 min
Standard solution: 0.01 mg/mL of doxycycline from USP Doxycycline Hyclate RS in *Medium*
Sample solution: Pass a portion of the solution under test through a suitable filter. Dilute a portion of the filtrate with *Medium* to a concentration that is similar to that of the *Standard solution*.

Instrumental conditions
(See *Ultraviolet-Visible Spectroscopy* ⟨857⟩.)
Mode: UV
Analytical wavelength: 268 nm
Cell: 1 cm
Blank: *Medium*
Analysis
Samples: *Standard solution* and *Sample solution*
Determine the percentage of the labeled amount of doxycycline ($C_{22}H_{24}N_2O_8$) dissolved:

$$\text{Result} = (A_U/A_S) \times (C_S/L) \times D \times V \times P \times F \times 100$$

A_U = absorbance of the *Sample solution*
A_S = absorbance of the *Standard solution*
C_S = concentration of USP Doxycycline Hyclate RS in the *Standard solution* (mg/mL)
L = label claim (mg/Tablet)
D = dilution factor for the *Sample solution*, if applicable
V = volume of *Medium*, 900 mL
P = potency of doxycycline in USP Doxycycline Hyclate RS (µg/mg)
F = conversion factor, 0.001 mg/µg

Tolerances: NLT 80% *(Q)* of the labeled amount of doxycycline ($C_{22}H_{24}N_2O_8$) is dissolved. ▲ (RB 1-Apr-2018)

• **UNIFORMITY OF DOSAGE UNITS** ⟨905⟩**:** Meet the requirements

IMPURITIES

• **ORGANIC IMPURITIES**

Protect solutions containing doxycycline from light.
Mobile phase, Diluent, and **Chromatographic system:** Proceed as directed in the *Assay*.
System suitability stock solution 1: 1 mg/mL each of USP Doxycycline Related Compound A RS and USP Methacycline Hydrochloride RS in *Diluent*
System suitability stock solution 2: 1.2 mg/mL of USP Doxycycline Hyclate RS in *Diluent*
System suitability solution: Transfer 5 mL of *System suitability stock solution 2* to a 25-mL volumetric flask, heat on a steam bath for 60 min, and evaporate to dryness on a hot plate, taking care not to char the residue. Dissolve the residue in *Diluent*, add 0.5 mL of *System suitability stock solution 1*, and dilute with *Diluent* to volume. Pass the solution through a suitable filter and use the filtrate. This solution contains a mixture of 4-epidoxycycline, doxycycline related compound A, methacycline, and doxycycline. [NOTE—The solution is stable up to 14 days when stored in a refrigerator at 2°–8°.]
Standard solution: 7.0 µg/mL of USP Doxycycline Hyclate RS in *Diluent*
Sample solution: Nominally 2.0 mg/mL of doxycycline from NLT 20 Tablets prepared as follows. Transfer a suitable portion of finely powdered Tablets to a suitable volumetric flask. Add 50% of the final volume of *Diluent*, dissolve, dilute with *Diluent* to volume, and mix well. Centrifuge a portion of the solution and use the supernatant. [NOTE—The use of a centrifuge speed at 3,000 rpm for 10 min may be suitable.]
System suitability
Samples: *System suitability solution* and *Standard solution*
Suitability requirements
Resolution: NLT 1.5 between methacycline and 4-epidoxycycline; NLT 1.5 between 4-epidoxycycline and doxycycline related compound A; NLT 2.0 between doxycycline related compound A and doxycycline, *System suitability solution*
Relative standard deviation: NMT 5.0% for the doxycycline peak, *Standard solution*
Analysis
Samples: *Standard solution* and *Sample solution*
Calculate the percentage of each impurity in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times P \times F \times 100$$

r_U = peak response of each impurity from the *Sample solution*
r_S = peak response of doxycycline from the *Standard solution*
C_S = concentration of USP Doxycycline Hyclate RS in the *Standard solution* (mg/mL)
C_U = nominal concentration of doxycycline in the *Sample solution* (mg/mL)
P = potency of doxycycline in USP Doxycycline Hyclate RS (µg/mg)
F = conversion factor, 0.001 mg/µg

Acceptance criteria: See *Table 2*. Disregard peaks less than 0.1%.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Methacycline[a, b]	0.64	—
4-Epidoxycycline[c]	0.79	1.5
Doxycycline related compound A (6-epidoxycycline)[b, d]	0.88	—
Doxycycline	1.0	—
Any individual unspecified impurity	—	0.3
Total impurities	—	2.5

[a] (4*S*,4a*R*,5*S*,5a*R*,12a*S*)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide.
[b] Process impurities that are controlled in the drug substance are not to be reported. They are not to be included in total impurities. They are listed here for information only.
[c] (4*R*,4a*R*,5*S*,5a*R*,6*R*,12a*S*)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide. Main degradation product.
[d] (4*S*,4a*R*,5*S*,5a*R*,6*S*,12a*S*)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide.

ADDITIONAL REQUIREMENTS

• **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers. Store at controlled room temperature.

Add the following:

▲• **LABELING:** When more than one *Dissolution* test is given, the labeling states the test used only if *Test 1* is not used. ▲ (RB 1-Apr-2018)

• **USP REFERENCE STANDARDS** ⟨11⟩
USP Doxycycline Hyclate RS
USP Doxycycline Related Compound A RS

[NOTE—May be available as a free base or a hydrochloride salt.]
(4*S*,4a*R*,5*S*,5a*R*,6*S*,12a*S*)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide.
$C_{22}H_{24}N_2O_8$ 444.43
(4*S*,4a*R*,5*S*,5a*R*,6*S*,12a*S*)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide, monohydrochloride.
$C_{22}H_{24}N_2O_8 \cdot HCl$ 480.13
USP Methacycline Hydrochloride RS